• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Castle Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8/8/25 4:04:57 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email
    cstl-20250805
    0001447362FALSE12/3100014473622025-08-052025-08-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 5, 2025

    Castle Biosciences, Inc.
    (Exact name of registrant as specified in its charter)
         
    Delaware 001-38984 77-0701774
    (state or other jurisdiction
    of incorporation)
     (Commission
    File Number)
     (I.R.S. Employer
    Identification No.)
    505 S. Friendswood Drive, Suite 401
    Friendswood, Texas
    77546
    (Address of principal executive offices)(Zip Code)

    Registrant’s telephone number, including area code: (866) 788-9007

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
     
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.001 par value per shareCSTL The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
    Emerging growth company ☐ 
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



    Item 5.03    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On August 5, 2025, the board of directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.

    The following is a summary of the material changes made to the Company’s amended and restated bylaws in effect prior to the adoption of the A&R Bylaws by the A&R Bylaws and is qualified in its entirety by reference to the full text of the A&R Bylaws, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and incorporated herein by reference.


    Bylaw §Bylaw Change
    1Cause the Bylaws to identify the registered office and agent by referencing the Company’s certificate of incorporation, as amended from time to time (the “Certificate of Incorporation”).
    5(a)Revise who has authority to postpone, reschedule or cancel a meeting of stockholders.
    Require that stockholders who wish to nominate directors for election to the Board must be stockholders of record at the time of the annual meeting in addition to at the time they give notice of their proposed nomination.
    Clarify how a stockholder may make nominations for the Board and submit other business to come before an annual meeting of stockholders.
    5(b)(i)Clarify the background information that must be provided regarding proponents of nominees to the Board and about the nominees themselves.
    Limit the maximum number of nominees to the Board that a stockholder may submit to be equal to the number of directors to be elected at the applicable meeting.
    Prohibit the nomination of substitute or alternate nominees to the Board without timely notice in accordance with the A&R Bylaws.
    5(b)(ii)Require advance disclosure of resolutions or amendments to the A&R Bylaws that are the subject of a proposal to be brought before an annual meeting of stockholders.
    5(b)(iii)Increase the period of time that an annual meeting date can be moved with respect to the anniversary of the previous year’s meeting date before an alternative window is applied for purpose of determining timely notice of stockholder proposals. As amended, the alternative window applies if the annual meeting date is advanced by more than 30 days prior to or delayed by more than 70 days (previously 30 days) after the anniversary of the preceding year’s annual meeting.
    5(b)(iv)Require additional information regarding proponents of stockholder proposals and director nominees and require such proponents to make certain representations and certifications related to the proposals or nominees, the proponents intended proxy solicitations, the cost of solicitation and the proponent’s compliance with applicable laws.
    5(c)Clarify the procedures for a proponent of stockholder proposals and director nominees to update the representations and certifications described in Section 5(b)(iv) above.
    5(d)Clarify the procedures to be followed in the event the number of directors to be elected to the Board at an annual meeting is increased and there is no public announcement about such increase.
    5(e)Clarify the provisions that require each proposed nominee to the Board to complete a written questionnaire and make certain representations and certifications about their candidacy, voting commitments, compensation for service and compliance with the Company’s corporate governance and other policies.
    5(f)Provide explicit procedures regarding the validity or invalidity of proposals to nominate persons to the Board and the effects of failure by a proponent to follow such procedures.
    Require the stockholder (or its qualified representative) proposing a nominee to the Board or any other stockholder business to be present at the meeting of stockholders in order to nominate or present the business.
    Incorporate the universal proxy rules in Rule 14a-19 under the Securities Exchange Act of 1934, as amended.



    Bylaw §Bylaw Change
    6(a)-(b)Add clarity regarding who can postpone, reschedule or cancel special meetings of stockholders, and clarify how the Board can call a special meeting of stockholders, including its determination of the time and place of a special meeting.
    6(c)-(e)Conform the advance notice procedures for stockholder proposals at a special meeting to the advance notice procedures for stockholder proposals at an annual meeting (as set forth in Section 5, discussed above).
    7Revise the provisions governing notice of meetings to conform to the current provisions in Section 222 of the General Corporation Law of the State of Delaware (“DGCL”).
    8
    Change the threshold for a quorum for stockholder meetings from:
    •the holders of a majority of the outstanding shares entitled to vote; to
    •the holders of a majority of voting power of the outstanding shares entitled to vote.
    Change the default threshold for approval of proposals at stockholder meetings from:
    •a majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter; to
    •a majority of votes cast on such matter, voting affirmatively or negatively (excluding abstentions and broker non-votes).
    9
    Change the threshold required to adjourn a stockholder meeting from:
    •approval by the chairman of the meeting or by the vote of a majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting; to
    •approval by the chairperson of the meeting or by the stockholders by the affirmative vote of a majority of the votes cast, voting affirmatively or negatively (excluding abstentions and broker non-votes).
    Obviate the need for the Company to provide a new notice for an adjourned meeting if the means of remote communication are announced at the meeting at which adjournment takes place or is displayed on the website used for purposes of remote stockholder participation at the adjourned meeting.
    10Require the stockholder soliciting proxies use a proxy card color other than the “white proxy” that is reserved for the Company.
    12Modify the required preparation procedures, content and availability of the list of stockholders entitled to vote at a meeting in connection with the current provisions of the DGCL.
    17Omit the description of the Board classes and director terms from the Bylaws and refer to the Certificate of Incorporation.
    20Cause the Bylaws to refer to the Certificate of Incorporation for determining the procedures related to removal of a director.
    22(a)Provide the Board additional flexibility in determining when to hold an adjourned special meeting.
    23
    Change the effective date of consents of the Board or committees from:
    •the date such consents are filed with the minutes of proceedings of the Board or committee; to
    •the date such consents are completed.
    25(d)
    Change the number of directors required for quorum of a committee of the Board from:
    •a majority of the authorized number of members of any such committee; to
    •a majority of the members of the committee then serving unless the committee consists of one or two members, in which event one member shall constitute quorum of such committee.
    33Modify the threshold required for the Board to remove an officer to make it consistent with the general threshold for Board actions described in Section 22(b).
    39(a)Add procedures for the Board to fix the record date for determining the stockholders entitled to notice of any meeting of stockholders and, separately, the record date for determining the stockholders entitled to vote at such meeting.



    Bylaw §Bylaw Change
    40(b)Clarify the Board’s authority over the issuance, transfer and registration of shares of the Company, including the authority to choose the transfer agent and registrar and to issue shares in uncertificated form.
    45(a)-(b)Expand the Company’s mandatory obligation to indemnify its directors and officers, and its discretionary authority to indemnify employees and other agents, to the maximum extent allowed by applicable law.
    Clarify the circumstances in which the Company is obligated to indemnify its directors and officers for certain claims brought against the Company and initiated by such a director or officer.
    Limit the Company’s obligation to advance expenses to its directors and officers for certain claims brought against the Company and initiated by such a director or officer unless such claims were authorized by the Board or were initiated to enforce rights to indemnification or advancement of expenses as provided for in Section 45(d) of the A&R Bylaws.
    45(c)Subject to the limitations in Section 45(a), expand the Company’s mandatory obligation to advance expenses to directors and officers of the Company to the maximum extent allowed by applicable law, and clarify the procedure by which a director or officer is determined to be entitled to such advancement of expenses.
    46(a)-(b)Clarify how notice may be delivered to stockholders and directors.
    46(g)Identify the procedures for waiver of notice for any meeting, whether the meeting is regular or special or for stockholders, the Board or a committee of the Board in one place.
    47Omit the specific threshold required for the Board to amend the A&R Bylaws so that the general threshold for Board actions described in Section 22(b) governs.
    49Remove the forum selection provisions from the A&R Bylaws in favor of the identical provisions that already exist in the Certificate of Incorporation.


    Item 9.01    Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit
    NumberDescription
    3.1
    Amended and Restated Bylaws of Castle Biosciences, Inc.
    104Inline XBRL for the cover page of this Current Report on Form 8-K.




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    CASTLE BIOSCIENCES, INC.
    By:/s/ Frank Stokes
    Frank Stokes
    Chief Financial Officer
    Date: August 8, 2025
     



    Get the next $CSTL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Castle Biosciences to Participate in Upcoming Investor Conferences

    FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast. Castle will also be available for one-on-one investor meetings during the Wells Far

    8/21/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports Second Quarter 2025 Results

    Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th

    8/4/25 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

    FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (NASDAQ:CSTL) is a leading di

    7/29/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    SEC Filings

    View All

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    8/15/25 5:19:20 PM ET
    $CSTL
    Medical Specialities
    Health Care

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    8/13/25 5:30:12 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

    8/8/25 4:04:57 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Exec. Officer Maetzold Derek J sold $26,834 worth of shares (1,339 units at $20.04), decreasing direct ownership by 2% to 68,344 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    8/19/25 4:04:43 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J sold $839,043 worth of shares (43,019 units at $19.50), decreasing direct ownership by 38% to 69,683 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    8/15/25 4:14:28 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J covered exercise/tax liability with 23,972 shares and converted options into 66,991 shares, increasing direct ownership by 62% to 112,702 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    8/12/25 4:32:21 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Castle Biosciences with a new price target

    Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

    12/14/23 6:54:55 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Castle Biosciences with a new price target

    Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

    1/5/23 7:53:37 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Stephens & Co. initiated coverage on Castle Biosciences with a new price target

    Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

    1/7/22 5:42:05 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

    The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

    4/30/24 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

    SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

    5/26/21 12:42:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Financials

    Live finance-specific insights

    View All

    Castle Biosciences Reports Second Quarter 2025 Results

    Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th

    8/4/25 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

    FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

    7/14/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports First Quarter 2025 Results

    Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

    5/5/25 4:06:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/13/24 6:44:33 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    7/8/24 4:32:39 PM ET
    $CSTL
    Medical Specialities
    Health Care